Management tracks: AstraZeneca, Certara, Longas

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sunil Verma will become VP, head of breast cancer strategy and global clinical leader in R&D oncology. Verma was head of the department of oncology at University of Calgary and medical director of the Tom Baker Cancer Centre.

Certara L.P. (Princeton, N.J.) hired William Feehery as CEO, effective June 3. Feehery, who is president of E. I. du Pont de Nemours and Co. (Wilmington, Del.) will also join the model-informed drug development company’s board. He succeeds CEO Edmundo Muniz, who will become a board member. Certara is developing a liquid biopsy test to enable precision drug dosing (See "Leaning on Exosomes, Model-informed Drug Development Gets Closer to Tailoring Doses to Each Patient")...